This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
BMY Reports Positive Data on Sotyktu From Arthritis Study
by Zacks Equity Research
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
NVSPositive Net Change BMYNegative Net Change BAYRYNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
NVO Stock Gains After Parvus Asset Management Builds Stake
by Zacks Equity Research
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
NVSPositive Net Change NVOPositive Net Change LLYPositive Net Change BAYRYNegative Net Change
biotechnology medical pharmaceuticals
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
by Zacks Equity Research
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
GSKNegative Net Change NVSPositive Net Change GILDPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
by Kinjel Shah
LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
pharmaceuticals
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
by Kinjel Shah
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
JNJPositive Net Change MRKPositive Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services
by Zacks Equity Research
JNJ, TMUS, BA, and FRAF show strong momentum as earnings growth, market share, and strategic moves fuel investor confidence.
BANegative Net Change JNJPositive Net Change TMUSPositive Net Change FRAFPositive Net Change
airlines communications finance pharmaceuticals
Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, T-Mobile US, and The Boeing Company.
BANegative Net Change JNJPositive Net Change SLBNegative Net Change TSLANegative Net Change TMUSPositive Net Change FRAFPositive Net Change CRWDPositive Net Change
airlines pharmaceuticals
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
SNYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals vaccines
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
AZNPositive Net Change NVSPositive Net Change BMYNegative Net Change PFEPositive Net Change LLYPositive Net Change ABBVPositive Net Change FATEPositive Net Change
biotechs cancer pharmaceuticals
Best Momentum Stocks to Buy for June 10th
by Zacks Equity Research
AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025.
AMRNPositive Net Change PATHPositive Net Change FIXPositive Net Change
pharmaceuticals
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
by Kinjel Shah
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
MRKPositive Net Change MRNAPositive Net Change SMMTPositive Net Change
pharmaceuticals
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
by Zacks Equity Research
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
ALNYPositive Net Change BAYRYNegative Net Change LXRXPositive Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
by Sundeep Ganoria
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Oracle, Novo Nordisk, Linde, NVE and CPS Technologies
by Zacks Equity Research
Zacks spotlights ORCL, NVO, LIN, NVEC and CPSH for their strategic growth plays, from AI cloud to medtech sensing and advanced materials.
NVOPositive Net Change ORCLPositive Net Change LINPositive Net Change NVECNegative Net Change CPSHNegative Net Change
computers industrial-products pharmaceuticals semiconductor tech-stocks
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
by Kinjel Shah
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change SMMTPositive Net Change
pharmaceuticals
Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space
by Ekta Bagri
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
REGNPositive Net Change SNYPositive Net Change NVSPositive Net Change BMYNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Top Research Reports for Oracle, Novo Nordisk & Linde
by Mark Vickery
ORCL gains on strong cloud momentum, while NVO battles obesity headwinds and LIN leans on $10B backlog for growth.
NVOPositive Net Change ORCLPositive Net Change LINPositive Net Change NVECNegative Net Change CPSHNegative Net Change
computers industrial-products pharmaceuticals semiconductor tech-stocks
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
by Zacks Equity Research
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
by Ekta Bagri
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
GRFSPositive Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
by Ekta Bagri
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure
BMYNegative Net Change PFEPositive Net Change MRKPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
by Sundeep Ganoria
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
REGNPositive Net Change AZNPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Zacks.com featured highlights JAKKS Pacific, Green Dot, Signet Jewelers, Gibraltar Industries and Pfizer
by Zacks Equity Research
JAKK, GDOT, SIG, ROCK, and PFE offer low P/S ratios and high growth potential, making them standout value plays now.
PFEPositive Net Change JAKKPositive Net Change SIGNegative Net Change GDOTPositive Net Change ROCKNegative Net Change
pharmaceuticals
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
BAYRYNegative Net Change LXRXPositive Net Change AMRNPositive Net Change ZTSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
by Zacks Equity Research
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
BAYRYNegative Net Change LXRXPositive Net Change AMRNPositive Net Change LYRANegative Net Change
biotechnology biotechs medical pharmaceuticals